Suppression of glucose uptake by TMEM16A also generates secondary effects by enhancing gluconeogenesis and glucose metabolic disorder, thereby exacerbating insulin resistance, lipogenic events, inflammatory responses, and other NAFLD‐related events (Figure 7E). This evidence concerns the gene ANO1 and metabolic dysfunction-associated steatotic liver disease.